Page 97 - 南京医科大学自然版

第44卷第4期 喻 悦，王瑜亮，张 晓. 葡萄糖代谢重编程在胰腺癌耐药中的研究进展［J］.
2024年4月 南京医科大学学报（自然科学版），2024，44（04）：524-535，572 ·535 ·

［61］SANTANA⁃CODINA N，ROETH A A，ZHANG Y，et al. 9949272
Oncogenic KRAS supports pancreatic cancer through regu⁃ ［73］QIN C，YANG G，YANG J S，et al. Metabolism of pancre⁃
lation of nucleotide synthesis［J］. Nat Commun，2018，9 atic cancer：paving the way to better anticancer strategies［J］.
（1）：4945 Mol Cancer，2020，19（1）：50
［62］SAEUI C T，SHAH S R，FERNANDEZ⁃GIL B I，et al. ［74］SUN L ，CAO J，CHEN K，et al. Betulinic acid inhibits
Anticancer properties of hexosamine analogs designed to stemness and EMT of pancreatic cancer cells via activa⁃
attenuate metabolic flux through the hexosamine biosyn⁃ tion of AMPK signaling［J］. Int J Oncol，2019，54（1）：98-
thetic pathway［J］. ACS Chem Biol，2023，18（1）：151-165 110
［63］LIU C，DENG S M，XIAO Z W，et al. Glutamine is a sub⁃ ［75］ZHAO H Q，WU S H，LI H H，et al. ROS/KRAS/AMPK
strate for glycosylation and CA19⁃9 biosynthesis through signaling contributes to gemcitabine ⁃ induced stem ⁃ like
hexosamine biosynthetic pathway in pancreatic cancer［J］. cell properties in pancreatic cancer［J］. Mol Ther Oncoly⁃
Discov Oncol，2023，14（1）：20 tics，2019，14：299-312
［64］RICCIARDIELLO F，GANG Y，PALORINI R，et al. Hexo⁃ ［76］KABASHIMA A，MATSUO Y，ITO S，et al. cGAS⁃STING
samine pathway inhibition overcomes pancreatic cancer signaling encourages immune cell overcoming of fibro⁃
resistance to gemcitabine through unfolded protein re⁃ blast barricades in pancreatic cancer［J］. Sci Rep，2022，
sponse and EGFR ⁃ Akt pathway modulation［J］. Onco⁃ 12（1）：10466
gene，2020，39（20）：4103-4117 ［77］JACOBERGER F C，COUSINEAU I，BARECHE Y，et al.
［65］JU H Q，ZHUANG Z N，LI H，et al. Regulation of the CD73 inhibits cGAS⁃STING and cooperates with CD39 to
Nampt⁃mediated NAD salvage pathway and its therapeu⁃ promote pancreatic cancer［J］. Cancer Immunol Res，
tic implications in pancreatic cancer［J］. Cancer Lett， 2023，11（1）：56-71
2016，379（1）：1-11 ［78］KOSAKA A，YAJIMA Y，YASUDA S，et al. Celecoxib pro⁃
［66］SHARMA N，BHUSHAN A，HE J，et al. Metabolic plasticity motes the efficacy of STING⁃targeted therapy by increas⁃
+
imparts erlotinib⁃resistance in pancreatic cancer by up⁃ ing antitumor CD8 T⁃cell functions via modulating glu⁃
+
+
regulating glucose⁃6⁃phosphate dehydrogenase［J］. Can⁃ cose metabolism of CD11b Ly6G cells［J］. Int J Cancer，
cer Metab，2020，8：19 2023，152（8）：1685-1697
［67］DENG J Y，GUO Y J，HU X M，et al. High glucose pro⁃ ［79］RAJESHKUMAR N V，YABUUCHI S，PAI S G，et al.
motes pancreatic ductal adenocarcinoma gemcitabine re⁃ Treatment of pancreatic cancer patient⁃derived xenograft
sistance and invasion through modulating ROS/MMP ⁃ 3 panel with metabolic inhibitors reveals efficacy of phen⁃
signaling pathway［J］. Oxid Med Cell Longev，2022， formin［J］. Clin Cancer Res，2017，23（18）：5639-5647
2022：3243647 ［80］RAEZ L E，PAPADOPOULOS K，RICART A D，et al. A
［68］KIM M J，KIM H S，KANG H W，et al. SLC38A5 modu⁃ phase I dose⁃escalation trial of 2⁃deoxy⁃D⁃glucose alone
lates ferroptosis to overcome gemcitabine resistance in or combined with docetaxel in patients with advanced solid
pancreatic cancer［J］. Cells，2023，12（20）：2509 tumors［J］. Cancer Chemother Pharmacol，2013，71（2）：
［69］MOSSMANN D，PARK S，HALL M N. mTOR signalling 523-530
and cellular metabolism are mutual determinants in can⁃ ［81］PHILIP P A，BUYSE M E，ALISTAR A T，et al. A Phase
cer［J］. Nat Rev Cancer，2018，18（12）：744-757 Ⅲ open ⁃ label trial to evaluate efficacy and safety of
［70］LIN M M，XIAO Y Y，DAI Y L，et al. Chloroxine inhibits CPI ⁃ 613 plus modified FOLFIRINOX（mFFX）versus
pancreatic cancer progression through targeted antago⁃ FOLFIRINOX（FFX）in patients with metastatic adeno⁃
nization of the PI3K/AKT/mTOR signaling pathway［J/ carcinoma of the pancreas［J］. Future Oncol，2019，15
OL］. Clin Transl Oncol，2023［2023 ⁃ 11 ⁃ 10］. DOI： （28）：3189-3196
10.1007/s12094⁃023⁃03328⁃w ［82］ALISTAR A，MORRIS B B，DESNOYER R，et al. Safety
［71］ALLEN E，MIÉVILLE P，WARREN C M，et al. Metabolic and tolerability of the first⁃in⁃class agent CPI⁃613 in com⁃
symbiosis enables adaptive resistance to anti⁃angiogenic bination with modified FOLFIRINOX in patients with
therapy that is dependent on mTOR signaling［J］. Cell metastatic pancreatic cancer：a single⁃centre，open⁃label，
Rep，2016，15（6）：1144-1160 dose⁃escalation，phase 1 trial［J］. Lancet Oncol，2017，18
［72］MA Z Y，LI Z C，MA Z G，et al. Development of a KRAS⁃ （6）：770-778
associated metabolic risk model for prognostic prediction ［83］BACHET J B，GAY F，MARÉCHAL R，et al. Asparagine
in pancreatic cancer［J］. Biomed Res Int，2021，2021： （下转第572页）